RAYNHAM, Mass., Feb. 5, 2018 /PRNewswire/ -- OMNIlife science™, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced that several presentations about their breakthrough OMNIBotics Active Spacer technology were featured at the International Congress for Joint Reconstruction (ICJR) 10th Annual Hip & Knee Conference held in Vail, CO from January 18-21.
The ICJR focuses on providing a comprehensive orthopaedic learning experience for their members, delivering timely and relevant education. The more than 150 attendees learned about OMNIBotics Active Spacer technology in both a pre-recorded surgery presentation and a podium presentation. The surgery, "TKA Utilizing OMNIBotics Active Spacer Robotically Assisted Ligament Balancing System" was performed and narrated by Jeffrey H. DeClaire, MD, DeClaire LaMacchia Orthopaedic Institute, Rochester Hills, MI. The podium presentation "Ligament Balancing Technology in TKA" was given by John Keggi, M.D., Connecticut Joint Replacement Institute, Hartford, CT.
Dr. DeClaire commented, "With this new technology and the ability to capture accurate data, the Active Spacer can help to more accurately and consistently restore the normal soft tissue balance of the knee with the potential to improve patient outcomes and patient satisfaction."
The OMNIBotics Active Spacer, with more than 150 procedures performed to date, provides the surgeon with a quantitative tool to actively manage the soft tissue envelope with dynamic real-time feedback. Since sub-optimal soft tissue balancing is a potential contributing factor to patient dissatisfaction with their knee replacement, OMNI developed this device to address that need. When the OMNIBotics Active Spacer is combined with the accuracy of alignment and bone cuts provided by the OMNIBotics system, the result is a completely customized procedure from both a skeletal and a soft tissue perspective.
"The Active Spacer provides the most accurate and useful information to date for achieving good balance in knee replacement patients," stated Dr. Keggi. "Surgeons can now see the full motion and precise balance of the knee in real time, which provides important feedback to optimize the function of the knee."
The OMNIBotics Active Spacer received FDA clearance in early September, 2017 and is currently in clinical evaluation at six sites in the United States and one in Australia.
OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon's ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms "plans," "believes" or similar expressions are "forward‐looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward‐looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.
Cindy Holloway, Director of Marketing Communications
Phone: (508) 824‐2444
SOURCE OMNIlife science, Inc.